In a nutshell The study evaluated the addition of pembrolizumab (Keytruda) to etoposide (Etopophos) and platinum chemotherapy drugs for patients with untreated extensive-stage (ES) small-cell lung cancer (SCLC). The study found that pembrolizumab improved progression-free survival (PFS; survival without cancer getting worse) when added to...
Read More
Video information: At the 2017 ASCO meeting in Chicago, Dr. George Simon and Dr. David Carbone talk about news and progress in small cell lung cancer. Dr. Simon goes into detail on some new promising approaches and current studies for small cell lung cancer treatment, adding "these are some of the newer, in my opinion, more exciting approaches...
Read More
In a nutshell The article evaluated the accuracy of YKL-40 levels to predict a patient’s response to chemotherapy for the treatment of SCLC and their cancer outcomes. Some background Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and has a low 5-year survival rate of 10-26% due to relapse (cancer...
Read MoreIn a nutshell This trial investigated whether chemotherapy drugs belonging to the class of camptothecins (such as irinotecan or topotecan) used together with platinum analog chemotherapy (such as cisplatin or carboplatin) were better than the standard regimens in treating extensive disease small-cell lung cancer. Some background Standard treatment...
Read More
